Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR Extension: Idalopirdine in Alzheimer's Disease
NCT02079246Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Apr 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of Idalopirdine in Alzheimer's disease (AD), sponsored by Lundbeck. Started Apr 2014; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02079246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079246.